Vanda Pharmaceuticals (NASDAQ:VNDA) is one of today's worst performing low-priced stocks, down 11.8% to $3.83 on 1.0x average daily volume. Thus far today, Vanda Pharmaceuticals has traded 426,000 shares, vs. average volume of 406,000 shares per day. The stock has underperformed the Dow (-11.8% to the Dow's -0.2%) and underperformed the S&P 500 (-11.8% to the S&P's -0.2%) during today's trading.

Vanda Pharmaceuticals (NASDAQ:VNDA) has potential upside of 63.2% based on a current price of $3.83 and analysts' consensus price target of $6.25. The stock should hit resistance at its 200-day moving average (MA) of $4.02, as well as support at its 50-day MA of $3.67.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of clinical-stage, small molecule product candidates for central nervous system disorders.

In the past 52 weeks, Vanda Pharmaceuticals share prices have been bracketed by a low of $2.92 and a high of $5.47 and are now at $3.83, 31% above that low price. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 2.1%.

SmarTrend recommended that subscribers consider buying shares of Vanda Pharmaceuticals on December 18th, 2012 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $4.09. Since that recommendation, shares of Vanda Pharmaceuticals have risen 6.1%. We continue to monitor VNDA for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.